Vaccine Technologies and Global Markets

Published - Jan 2008| Analyst - Vanita Khetan| Code - PHM014C
Market Research Report Single User License: $2750 Member Price: FREE

Report Highlights

  • The global market for vaccines is expected to reach $22.4 billion by the end of 2008. It should reach $36.3 billion by 2013, a com¬pound annual growth rate (CAGR) of nearly 11%.
  • Although pediatric vaccines traditionally have had the largest share of the market, adult and therapeutic vaccines will likely usurp this position in the near future.
  • Patent activity has heightened to an almost frenzied level over the study period, with as many as 250 each year for 2006 and 2007.


Through the late 1980s, the vaccine market was beset by limited portfolios and profitability. Recent technological breakthroughs in understanding disease mechanisms, probably necessitated by pandemics and vaccine shortages, have provided momentum for research in the past decade or so. This is apparent from the increased research, patent, and regulatory activity in this area. Breakthroughs in molecular biology, immunology, and computing promise a bright future for the treatment of not only infectious diseases but also for treatment of conditions such as chronic infections, cancer, autoimmune diseases, allergies, and even nicotine addiction and high blood pressure using vaccine technologies. Advances are also being made in almost all adjunct areas of vaccine research, such as the mode of delivery, use of combination vaccines, vaccine adjuvants, and vaccine manufacturing.

The market has also witnessed significant strategic alliance activity, changes in centers of manufacture, and an increase in the importance of hitherto small (such as adult vaccines) or nonexistent (therapeutic) segments.

Most of all, international health agencies have recognized the importance of disease prevention and stupendous funding is being channelized into research, purchase, and administration of vaccines.


This report contains:


  • Descriptions of various human and veterinary vaccines that treat infectious diseases, chronic infections, cancer, auto-immune diseases, allergies, high blood pressure and addictions
  • The current market status of the vaccine industry, with trends and forecasts for growth over the next 5 years
  • The latest vaccine research findings in prophylactic and therapeutic areas
  • Analysis of significant vaccine-related patents in the Unites States and Europe
  • An overview of the regulatory environment.



BCC's methodology for market analysis and forecast projections includes both primary and secondary research sources. Market growth calculations take into account all factors that are likely to spur or inhibit market growth. Revenue figures are not corrected for inflation.


Data were compiled from industry experts and other stakeholders as well as various secondary sources such as government, nongovernment industry stakeholders, technology and market publications, and other public research data sources.


Vanita Khetan is a market analyst who has authored several BCC technology market research reports. She holds a bachelor's degree in chemistry and a post graduate degree in management. During her career, she has analyzed U.S., European, and Asian markets in biotechnology, pharmaceuticals, medical devices, wound care, and surgical goods. She has also worked in the Indian vaccine industry for about 2 years.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at
Note: Reports are discounted or included with certain Memberships. See Membership Options.
Published - Sep-2001| Analyst - Lynn Gray| Code - PHM014B

Report Highlights

  • The total worldwide market for prophylactic and therapeutic vaccines is estimated to be $5.8 billion in 2001.
  • Growing at an average annual rate (AAGR) of 11.6%, this market is expected to approach $10 billion in 2006.
  • Pediatric prophylactic vaccines make up 58% of the current market, but will show the slowest growth, at an AAGR of 8.7% through 2006.
  • Adult prophylactic vaccines are the second largest group with sales of nearly $2.4 billion in 2001 and are expected to rise at an AAGR of 10.1% to more than $3.8 billion in 2006.
  • Therapeutic vaccines will feature growth of more than 100% on average per year through the period, but by 2006 will still make up only 10.5% of the market.


Need a custom data table, graph or complete report? Tell us more.

Contact Us
Share This Report